socalTECH

JANUARY 6, 2011

Thousand Oaks-based Amgen , and Monrovia-based Xencor said Thursday that the two firms are in a co-development dual around a new novel antibody for treating autoimmune diseases. The deal also includes tiered royalties on future sales of XmAb5871. READ MORE>>.

Develop 191

Develop Development Thousand Oaks Monrovia 191

socalTECH

FEBRUARY 11, 2020

Monrovia, California-based AeroVironment , which develops unmanned aerial vehicles, said late Monday that it has received a $8.5M military sales contract from an un-named, U.S. According to AeroVironment, the $8,584,734 firm-fixed-price U.S.

Outsource Development 113

Outsource Development Monrovia Training Sales 113

socalTECH

DECEMBER 15, 2010

Monrovia-baesd Tanner EDA , the developer of mixed signal electronic design automation software, said today that it has expanded its presence in the Chinese market, and has signed up a new sales and support partner. to provide sales and support for all of its products in China.

Sales 150

Sales Monrovia Design Software 150

socalTECH

NOVEMBER 10, 2009

Monrovia-based Tanner EDA , a supplier of analog and mixed-signal electronic design automation software, reported Monday evening that it has appointed a new Sales VP, and separately, that it is in a strategic alliance with a MEMS supplier. Tanner said the two are working with Tanner EDA's Indian distributor, Trident Techlabs Pvt.

Sales 124

Sales Monrovia Design Software 124

socalTECH

APRIL 17, 2013

Monrovia, California-based biotherapeutics technology developer Xencor said Tuesday that it has licensed its Xtend technology to an Australian firm. Xencor and CSL Limited said they are in a technology license agreement, which will provide CSL access ot its technology, for use with CSL''s monoclonal antibodies. READ MORE>>.

Technology 147

Technology Monrovia Sales Product 147

socalTECH

SEPTEMBER 16, 2015

Thousand Oaks-based Amgen , and Monrovia, California-based Xencor said this morning they are in a strategic collaboration worth as much as $1.7 billion to Xencor, to develop and commercialize cancer immunotherapy and inflammation drugs. The two said that Amgen will pay Xencor $45M upfront, with the potential of up to $1.7

Thousand Oaks 100

Thousand Oaks Monrovia Platform Sales 100

socalTECH

JULY 2, 2013

Monrovia-based Xencor announced today that it is in a technology license and option agreement with biotech giant Merck. Xencor is developing antibody technology which it has widely licensed to companies such as Amgen, Pfizer, Janssen R&D LLC, MorphoSys, Boehringer Ingelheim, CSL Ltd. Financial terms of that deal were not announced.

Patents 138

Patents Monrovia Sales Technology 138